Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SMA
SMA
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Fierce Pharma
Sun, 06/20/21 - 10:21 pm
Novartis
SMA
spinal muscular atrophy
Zolgensma
Roche
Evresdi
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Xtalks
Tue, 06/8/21 - 12:19 pm
Novartis
Zolgensma
SMA
gene therapy
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
Wed, 04/28/21 - 10:27 am
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Biogen Reports New Spinraza Data in SMA
Global Genes
Wed, 04/21/21 - 10:34 am
Biogen
Spinraza
SMA
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche
Pharmaforum
Thu, 04/15/21 - 10:02 am
Roche
Genentech
Evrysdi
SMA
Scholar Rock eyes phase 3 after confirming effects of SMA drug
Fierce Biotech
Tue, 04/6/21 - 10:28 am
Scholar Rock
SMA
apitegromab
clinical trials
Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's
Endpoints
Wed, 10/21/20 - 11:43 pm
Novartis
SMA
branaplam
Huntington's disease
Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap
Fierce Biotech
Wed, 10/21/20 - 10:58 am
Biogen
earnings
opicinumab
MS
SMA
BIIB089
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
FDA sets back Novartis plans to expand use of SMA gene therapy
BioPharma Dive
Wed, 09/23/20 - 10:39 am
Novartis
SMA
gene therapy
Zolgensma
clinical trials
FDA
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
BioSpace
Wed, 08/12/20 - 12:14 am
Biogen
SMA
spinal muscular atrophy
Spinraza
clinical trials
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
Xconomy
Sat, 08/8/20 - 10:56 pm
Roche
risdiplam
SMA
spinal muscular atrophy
FDA
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Tue, 07/21/20 - 10:37 am
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
Beckers Hospital Review
Thu, 06/11/20 - 10:46 pm
OptumRx
Roche
PTC Therapeutics
risdiplam
SMA
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Immunomedics
Trodelvy
triple negative breast cancer
Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients
BioSpace
Wed, 06/10/20 - 11:46 pm
Biogen
SMA
Spinraza
clinical trials
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Wed, 05/20/20 - 10:50 am
Novartis
Zolgensma
SMA
spinal muscular atrophy
gene therapy
Europe
Roche shares SMA data ahead of scrap with Biogen, Novartis
Fierce Biotech
Tue, 04/28/20 - 10:59 am
Roche
Biogen
Novartis
SMA
spinal muscular atrophy
risdiplam
clinical trials
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Fierce Pharma
Wed, 04/8/20 - 11:03 am
Roche
FDA
risdiplam
Biogen
Spinraza
Novartis
Zolgensma
SMA
FDA delays decision on Roche spinal muscular atrophy drug
Biopharma Dive
Tue, 04/7/20 - 07:14 pm
FDA
Roche
SMA
risdiplam
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy
Xconomy
Tue, 03/31/20 - 10:49 am
SMA
Novartis
gene therapy
Zolgensma
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »